Description
Navivumab(TD-VK515036) is a research-grade recombinant antibody targetingHA/Hemagglutinin. Produced in mammalian cells with native-like glycosylation.HighlightsResearch Grade— For PK/PD studies, assay development, and ADA research.Native Glycosylation— Mammalian expression ensures native-like patterns.